StreetInsider.com News Articles

Form 10-K Bone Biologics Corp For: Dec 31

Mon, 02 Mar 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260302/26092957.html

Form 10-K Bone Biologics Corp For: Dec 31

Mon, 02 Mar 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260302/26092957.html

Form 4 Bone Biologics Corp For: Jan 08 Filed by: Frelick Jeff

Wed, 21 Jan 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260121/25875914.html

Form 4 Bone Biologics Corp For: Jan 08 Filed by: Frelick Jeff

Wed, 21 Jan 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260121/25875914.html

Form 4 Bone Biologics Corp For: Jan 08 Filed by: Walsh Deina H

Wed, 21 Jan 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260121/25875916.html

Form 4 Bone Biologics Corp For: Jan 08 Filed by: Walsh Deina H

Wed, 21 Jan 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260121/25875916.html

Form 8-K Bone Biologics Corp For: Jan 08

Thu, 08 Jan 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260108/25823478.html

Form 8-K Bone Biologics Corp For: Jan 08

Thu, 08 Jan 2026 08:06:00 -0400

si-local-file:///var/storage/secattach/20260108/25823478.html

Bone Biologics extends rhNELL-1 product shelf life to 24 months

Tue, 23 Dec 2025 08:05:12 -0400

Bone Biologics Corporation (NASDAQ: BBLG) announced that its rhNELL-1 product shelf life has been extended to 24 months, according to a company statement.

The orthobiologic product developer said the extended shelf life was validated by ongoing stability data and represents progression from previously validated 12-month and 18-month shelf-life milestones.

"This milestone reflects continued execution against our development and manufacturing objectives," said Jeff Frelick, Chief Executive Officer. "We believe extending the expected shelf life of rhNELL-1 to 24 months, as previously forecasted, is an important step toward commercialization, improving manufacturing efficiency, supply-chain flexibility, and product readiness."

The company stated the extended shelf life is

Form 10-Q Bone Biologics Corp For: Sep 30

Fri, 14 Nov 2025 16:41:00 -0400

si-local-file:///var/storage/secattach/20251114/25618447.html

Form 10-Q Bone Biologics Corp For: Sep 30

Fri, 14 Nov 2025 16:41:00 -0400

si-local-file:///var/storage/secattach/20251114/25618447.html

Form SCHEDULE 13G/A Bone Biologics Corp Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 07 Nov 2025 17:24:00 -0400

si-local-file:///var/storage/secattach/20251107/25579509.html

Form SCHEDULE 13G/A Bone Biologics Corp Filed by: INTRACOASTAL CAPITAL, LLC

Fri, 07 Nov 2025 17:24:00 -0400

si-local-file:///var/storage/secattach/20251107/25579509.html

Form S-8 Bone Biologics Corp

Fri, 26 Sep 2025 17:01:00 -0400

si-local-file:///var/storage/secattach/20250926/25385404.html

Form S-8 Bone Biologics Corp

Fri, 26 Sep 2025 17:01:00 -0400

si-local-file:///var/storage/secattach/20250926/25385404.html

Form 8-K Bone Biologics Corp For: Sep 04

Thu, 04 Sep 2025 07:05:00 -0400

si-local-file:///var/storage/secattach/20250904/25295127.html

Form 8-K Bone Biologics Corp For: Sep 04

Thu, 04 Sep 2025 07:05:00 -0400

si-local-file:///var/storage/secattach/20250904/25295127.html

Bone Biologics expects to complete clinical trial enrollment by year-end

Thu, 04 Sep 2025 07:00:34 -0400

Bone Biologics Corporation (NASDAQ: BBLG, BBLGW) announced that CEO Jeffrey Frelick issued a letter to stockholders outlining the company's progress on its NB1 bone graft product and upcoming milestones.

The company is conducting a pilot clinical study in Australia evaluating NB1, which combines recombinant human protein NELL-1 with demineralized bone matrix. The multicenter study examines two concentrations of NB1 compared to autograft control in up to 30 patients undergoing spinal fusion surgery for degenerative disc disease.

Frelick stated that clinical trial enrollment has been slower than anticipated but expects completion by the end of 2024. The study's primary endpoints include fusion success

Bone Biologics expects to complete clinical trial enrollment by year-end

Thu, 04 Sep 2025 07:00:34 -0400

Frelick stated that clinical trial enrollment has been slower than anticipated but expects completion by the end of 2024. The study's primary endpoints include fusion success

Bone Biologics expects to complete clinical trial enrollment by year-end

Thu, 04 Sep 2025 07:00:34 -0400

Frelick stated that clinical trial enrollment has been slower than anticipated but expects completion by the end of 2024. The study's primary endpoints include fusion success

Bone Biologics expects to complete clinical trial enrollment by year-end

Thu, 04 Sep 2025 07:00:34 -0400

Frelick stated that clinical trial enrollment has been slower than anticipated but expects completion by the end of 2024. The study's primary endpoints include fusion success

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Thu, 04 Sep 2025 07:00:00 -0400

BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (“Bone Biologics” or the “Company”) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders.

To My Fellow Stockholders:

I am pleased to provide a progress report on Bone Biologics’ development of NB1 and to review our expected milestones for the coming year, including the anticipated completion of enrollment in our first-in-human study and an interim update. As a reminder, NB1 consists of the recombinant human protein NELL-1 (rhNELL-1) combined with demineralized bone matrix (DBM).

NELL-1

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Thu, 04 Sep 2025 07:00:00 -0400

To My Fellow Stockholders:

NELL-1

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Thu, 04 Sep 2025 07:00:00 -0400

To My Fellow Stockholders:

NELL-1

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

Thu, 04 Sep 2025 07:00:00 -0400

To My Fellow Stockholders:

NELL-1